Novavax, Inc.
Could not find a ticker for this position, may be a filing error
A maker of protein-based vaccines against infectious diseases, this Maryland biotech is best known for Nuvaxovid, its COVID-19 shot that delivers pre-made spike proteins grown in moth cells rather than genetic instructions. Founded in 1987 and spun off from its parent IGI in 1995, it gained its Matrix-M immune-boosting adjuvant by buying Sweden's Isconova in 2013. The name blends "nova" (new) with "vax" (vaccine).
3.75% Convertible Senior Notes due 2023
Granted 150.2K
Granted 56.3K
Granted 55.4K
Granted 37.5K
Granted 18.9K
Granted 18.9K
Granted 18.9K
Granted 18.9K
Granted 18.9K
Granted 18.9K
Granted 9.5K
Granted 7.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Jacobs John CPresident and CEO, Director · 2 transactions | +2.6% | 225.7K | 150.2K | — | — |
| O'Hara ElaineEVP, Chief Strategy Officer · 2 transactions | +129.5% | 157.1K | 56.3K | — | — |
| Kelly James PatrickEVP, CFO and Treasurer · 4 transactions | +88.6% | 130.6K | 55.4K | — | — |
| Casey Mark JEVP, Chief Legal Officer · 2 transactions | +37.1% | 101.4K | 37.5K | — | — |
| Mott David MDirector · 1 transaction | +31% | 79.8K | 18.9K | — | — |
| Douglas RichardDirector · 1 transaction | +34.7% | 73.2K | 18.9K | — | — |
| Alton Gregg HDirector · 1 transaction | +65.5% | 47.7K | 18.9K | — | — |
| Rodgers Richard JDirector · 1 transaction | +66.3% | 47.4K | 18.9K | — | — |
| McGlynn Margaret GDirector · 1 transaction | +73.8% | 44.5K | 18.9K | — | — |
| King Rachel K.Director · 1 transaction | +75% | 44.1K | 18.9K | — | — |
| Newton Charles W.Director · 1 transaction | — | 9.5K | 9.5K | — | — |
| Shiver John W.Director · 1 transaction | — | 7.9K | 7.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.